Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

Leukemia

Volumn 24, Issue 6, 2010, Pages 1223-1227

  Redaelli, S ^a   Boschelli, F ^b   Perini, P ^a   Pirola, A ^a   Viltadi, M ^a   Gambacorti Passerini, C ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; HYDROXYUREA; IMATINIB; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRILE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; CANCER PATIENT; CASE REPORT; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN U937; CHRONIC MYELOID LEUKEMIA; DNA SYNTHESIS; DRUG POTENTIATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; LETTER; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NITRILES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; QUINOLINES; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 77954600200     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.79     Document Type: Letter

References (9)

1. Gambacorti-Passerini C, Gunby R, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85. (Pubitemid 36196725)
2. Puttini M, Coluccia AML, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-11322. (Pubitemid 46009962)
3. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M et al. Activity of bosutinib, dasatinib, and nilotinib against 18. imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469-471.
4. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23: 477-485.
5. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
6. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-1766. (Pubitemid 30120840)
7. Apperley J. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029. (Pubitemid 47629897)
8. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007; 109: 2112-2120. (Pubitemid 46348213)
9. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064-4072. (Pubitemid 350248463)